FMP
Regencell Bioscience Holdings Limited
RGC
NASDAQ
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
18.5 USD
5.88 (31.78%)
RGC Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-4M
-4.96M
-5.27M
-767.31k
Net Income
-4.36M
-6.06M
-7.59M
-1.35M
Depreciation & Amortization
745.59k
769.69k
604.4k
26.46k
Deferred Income Taxes
0
1.42k
0
0
Stock Based Compensation
449.31k
922.62k
2.76M
0
Change in Working Capital
-585.37k
-508.94k
-1.02M
552.98k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
0
0
0
0
Other Working Capital
-585.37k
-508.94k
-1.02M
552.98k
Other Non-Cash Items
-248k
-85.4k
-10.73k
52.91k
CF from Investing Activities
5.24M
58.98k
-10.78M
0
Investments in Property, Plant & Equipment
-5.38k
-27.39k
-780.88k
0
Net Acquisitions
0
970
0
0
Investment Purchases
-5M
-10M
-10M
0
Sales/Maturities of Investments
10.25M
10.09M
0
0
Other Investing Activites
0
86.37
-10k
0
CF from Financing Activities
102.28k
134.91k
22.41M
439.75k
Debt Repayment
0
0
-431.97k
-612.06k
Common Stock Issued
0
0
22.67M
0
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
102.28k
134.91k
-267.97k
-172.31k
Free Cash Flow
-4.01M
-4.99M
-6.05M
-767.31k
Operating Cash Flow
-4M
-4.96M
-5.27M
-767.31k
Capital Expenditures
-5.38k
-27.39k
-780.88k
0
Cash at Beginning of Period
1.56M
6.42M
59.41k
386.98k
Cash at End of Period
2.96M
1.56M
6.42M
59.41k
Net Change In Cash
1.4M
-4.85M
6.36M
-327.57k
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-17.32M
-11.44M
-4M
-2.65M
Net Income
-4.3M
-5.87M
-7.42M
-1.35M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-21.62M
-17.32M
-11.44M
-4M
Other Distributions
-4.3M
-5.87M
-7.45M
-1.35M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
226.51k
891.91k
1.46M
81.86k
Annual Depreciation
745.59k
769.69k
604.4k
26.46k
Capital Expenditure
-5.38k
-27.39k
-780.88k
0
Net PPE
-513.7k
149.62k
1.64M
55.41k
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
